Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Kivu Bioscience Inc.
Bayer
Kaiser Permanente
Children's Oncology Group
Institute of Cancer Research, United Kingdom
SEED Therapeutics, Inc.
MacroGenics
UNC Lineberger Comprehensive Cancer Center
Solve Therapeutics
National Institutes of Health Clinical Center (CC)
Tanabe Pharma America, Inc.
Blueprint Medicines Corporation
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Leap Therapeutics, Inc.
National Cancer Institute (NCI)
PharmaMar
NextPoint Therapeutics, Inc.
University of South Florida
Agenus Inc.
Memorial Sloan Kettering Cancer Center
Brown University
Xencor, Inc.
Prelude Therapeutics
University Hospital, Gasthuisberg
Innolake Biopharm
Celon Pharma SA
Corvus Pharmaceuticals, Inc.
pharmaand GmbH
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
University of Manchester
NKGen Biotech, Inc.
Merrimack Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Alliance for Clinical Trials in Oncology
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Dartmouth-Hitchcock Medical Center
European Organisation for Research and Treatment of Cancer - EORTC
INSYS Therapeutics Inc
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)